Skip to main content
SpringerLink
Log in

Response to Dr. Mahan Regarding Key Points to Consider When Evaluating Andexxa for Formulary Addition

  • Letters to the editor
  • Published:
Neurocritical Care Aims and scope Submit manuscript

A Letters to the editor to this article was published on 22 June 2020

The Original Article was published on 22 October 2019

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Saposnik G, Redelmeier D, Ruff CC, Tobler PN. Cognitive biases associated with medical decisions: a systematic review. BMC Med Inf Decis Mak. 2016;16(1):138.

    Article  Google Scholar 

  2. Avorn J. Academic detailing: “marketing” the best evidence to clinicians. JAMA. 2017;317(4):361–2.

    Article  Google Scholar 

  3. Coleman CI, Danese S, Ulloa J, Xiao G, Lovelace B. Real-world management of oral factor Xa inhibitor bleeding-related hospitalizations with andexanet alfa or 4 factor prothrombin complex concentrate. J Am Coll Cardiol. 2020;75(11):2209.

    Article  Google Scholar 

  4. Kaatz S, Mahan CE, Nakhle A, Gunasekaran K, Ali M, Lavender R, Paje DG. Management of elective surgery and emergent bleeding with direct oral anticoagulants. Curr Cardiol Rep. 2017;19(12):124.

    Article  Google Scholar 

  5. Strein M, May S, Brophy GM. Anticoagulation reversal for intracranial hemorrhage in the era of the direct oral anticoagulants. Curr Opin Crit Care. 2020;26(2):122–8.

    PubMed  Google Scholar 

  6. Home [Internet]. NICE. [cited 2020 May 15]. https://www.nice.org.uk/consultations/891/1/recommendations.

  7. Green L, Tan J, Antoniou S, Alikhan R, Curry N, Everington T, et al. Haematological management of major bleeding associated with direct oral anticoagulants—UK experience. Br J Haematol. 2019;185(3):514–22.

    Article  CAS  Google Scholar 

  8. Wilsey HA, Bailey AM, Schadler A, Davis GA, Nestor M, Pandya K. Comparison of low- versus high-dose four-factor prothrombin complex concentrate (4F-PCC) for factor Xa inhibitor-associated bleeding: a retrospective study. J Intensive Care Med. 2020. https://doi.org/10.1177/0885066620916706.

    Article  PubMed  Google Scholar 

  9. Cohen AT, Lewis M, Connor A, Connolly S, Yue P, Curnutte J, et al. 30 day mortality following andexanet alfa in Annexa-4 compared with prothrombin complex concentrate (PCC) therapy in the orange study for life threatening non-vitamin K oral anticoagulant (NOAC) related bleeding. J Am Coll Cardiol. 2020;75(Supp 11):2242.

    Article  Google Scholar 

  10. Barra ME, Das AS, Hayes BD, et al. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. J Thromb Haemost. 2020. https://doi.org/10.1111/jth.14838.

    Article  PubMed  Google Scholar 

  11. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med. 2017;377(5):431–41.

    Article  CAS  Google Scholar 

  12. Frontera JA, Bhatt P, Lalchan R, et al. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage. J Thromb Thrombolysis. 2020;49(1):121–31.

    Article  CAS  Google Scholar 

  13. Fda.gov. Summary Basis for Regulatory Action [Internet]. 2017 [cited 14 May 2020]. https://www.fda.gov/media/113954/download.

  14. Yin E, McConnell KJ. Request for an Andexxa value analysis. Ann Pharmacother. 2020. https://doi.org/10.1177/1060028020902280.

    Article  PubMed  Google Scholar 

  15. Christensen H, Cordonnier C, Korv J, Lal A, Ovesen C, Purrucker JC, et al. European stroke organisation guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage. Eur Stroke J. 2019;4(4):294–306.

    Article  Google Scholar 

  16. Home [Internet]. NICE. [cited 2020 May15]. Available from: https://www.nice.org.uk/guidance/GID-TA10440/documents/129.

Download references

Funding

The authors as listed above have received no source of financial support for this manuscript.

Author information

Authors and Affiliations

  1. Pharmacy and Therapeutics Committee Chair, St. Jude Medical Center, 101 Val Mesa Drive, Fullerton, CA, 92835, USA

    Harry Peled

  2. Department of Pharmacy Practice, Marshall B. Ketchum University College of Pharmacy, Fullerton, CA, USA

    Nhu Quyen Dau

  3. Southern California Regional Clinical Quality and Risk Manager, Providence St. Joseph Health, Irvine, CA, USA

    Helen Lau

Authors
  1. Harry Peled
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nhu Quyen Dau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Helen Lau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harry Peled.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peled, H., Dau, N.Q. & Lau, H. Response to Dr. Mahan Regarding Key Points to Consider When Evaluating Andexxa for Formulary Addition. Neurocrit Care 33, 327–329 (2020). https://doi.org/10.1007/s12028-020-01007-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12028-020-01007-0

Search

Navigation